Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0HZ2E
|
||||
| Former ID |
DNC000911
|
||||
| Drug Name |
M100907
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Sleep disorders [ICD9: 307.4, 327, 780.5; ICD10:F51, G47] | Phase 3 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H28FNO3
|
||||
| Canonical SMILES |
COC1=CC=CC(=C1OC)C(C2CCN(CC2)CCC3=CC=C(C=C3)F)O
|
||||
| InChI |
1S/C22H28FNO3/c1-26-20-5-3-4-19(22(20)27-2)21(25)17-11-14-24(15-12-17)13-10-16-6-8-18(23)9-7-16/h3-9,17,21,25H,10-15H2,1-2H3/t21-/m1/s1
|
||||
| InChIKey |
HXTGXYRHXAGCFP-OAQYLSRUSA-N
|
||||
| CAS Number |
CAS 139290-65-6
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
7979872, 11056395, 12014670, 14755501, 14804188, 39340971, 80773858, 91616570, 103275460, 103992797, 114155712, 124954269, 128128333, 134341108, 135650573, 137231458, 143057684, 144210564, 162249020, 164766144, 170500892, 176224358, 185997000, 198966064, 208265419, 215780295, 223532818, 223782286, 226970760, 241034286, 249735007, 252157845, 252159862, 252322025, 252821118
|
||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 2A receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Serotonergic synapse | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| PANTHER Pathway | 5HT2 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | ||||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
| SIDS Susceptibility Pathways | |||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00495885) Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus. U.S. National Institutes of Health. | ||||
| REF 2 | Antagonism of 5-hydroxytryptamine(2a) receptors attenuates the behavioral effects of cocaine in rats. J Pharmacol Exp Ther. 2001 Apr;297(1):357-63. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.